The company is investing in its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
Lonza announced on Oct. 22, 2020 that it is investing $93 million into its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
According to a company press release, the investment will be made over the course of two years at Lonza’s manufacturing sites in Bornem, Belgium; Colmar, France; Greenwood, SC; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.
"We continue to see strong demand for our products across all markets, as consumers and patients alike take a more active interest in their health,” said Claude Dartiguelongue, president, Capsules and Health Ingredients, Lonza, in the press release. “Therefore, we felt it is critical that we make this commitment to expand the manufacturing capacity of our network, not only addressing supply needs in the near term but also supply availability over the long term."
"Dosage form technologies have evolved rapidly over the past ten years,” added Stef Vanquickenborne, head of Capsules and Health Ingredients Research and Development, Lonza, in the press release. “As the leader in the industry, we are committed to innovation and helping our customers successfully deliver next-generation drugs and nutritional supplements."
Source: Lonza
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.